|
EIF2C3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.72659680891729E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.68354260824344E-14 |
| Normal-vs-Stage2 |
1.4009999826925E-09 |
| Normal-vs-Stage3 |
4.44966286039516E-12 |
| Normal-vs-Stage4 |
1.03980157817318E-11 |
| Stage1-vs-Stage2 |
3.088000E-01 |
| Stage1-vs-Stage3 |
4.845800E-02 |
| Stage1-vs-Stage4 |
3.585700E-02 |
| Stage2-vs-Stage3 |
6.768600E-01 |
| Stage2-vs-Stage4 |
5.417600E-01 |
| Stage3-vs-Stage4 |
7.906800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
8.27760000000621E-05 |
| Normal-vs-Asian |
9.43509714801394E-11 |
| Caucasian-vs-AfricanAmerican |
3.929600E-01 |
| Caucasian-vs-Asian |
3.972200E-01 |
| AfricanAmerican-vs-Asian |
1.669230E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.21351842305739E-12 |
| Normal-vs-Female |
1.62503344114384E-12 |
| Male-vs-Female |
4.955800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.28870003557324E-09 |
| Normal-vs-Age(41-60Yrs) |
6.55031584528842E-15 |
| Normal-vs-Age(61-80Yrs) |
1.35770283904435E-11 |
| Normal-vs-Age(81-100Yrs) |
6.447800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.181390E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.486200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.803600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.235600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.500200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.251600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.241900E-03 |
| Classical-VS-Follicular |
3.107400E-01 |
| Classical-VS-Other |
2.066600E-01 |
| Classical-VS-Normal |
1.19520005004148E-09 |
| Tall-VS-Follicular |
1.526750E-01 |
| Tall-VS-Other |
9.055400E-01 |
| Tall-VS-Normal |
7.157274772851E-12 |
| Follicular-VS-Other |
2.700200E-01 |
| Follicular-VS-Normal |
4.35140035115467E-10 |
| Other-VS-Normal |
2.2114000000073E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.06640260458357E-11 |
| Normal-vs-N1 |
5.94350013649603E-10 |
| N0-vs-N1 |
7.466200E-01 |
|
|
